Ullem, who has held the position for more than a decade, will transition to an advisory role after his replacement is named by mid-2026.

Trials from Edwards, Philips and Penumbra were among the most-watched studies at the annual cardiovascular meeting.

Edwards Lifesciences has raised its fiscal year (FY25) guidance to between $2.56 to $2.62 per share after achieving better ...

Jefferies and Wolfe Research both upgraded Edwards Lifesciences EW) with Jefferies citing recent strong data for the SAPIEN ...

S AN FRANCISCO -- Long-term outcomes after transcatheter aortic valve replacement (TAVR) were looking more and more like ...

The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

Medtronic today announced the launch of its Stedi extra support guidewire for use with its Evolut TAVR platform.

Expanding your horizons and considering neglected sectors can help you identify bargain opportunities while defending your ...

The companies agreed to enhance access to technology from DASI, a leader in AI-driven predictive modeling and digital twin technology. They aim to optimize outcomes for patients undergoing ...

GLASGOW, SCOTLAND - MAY 22: Dr Catherine Calderwood (2L), Chief Medical Officer for Scotland, Professor Sir Pete Downes, Principal and Vice Chancellor (2R), Dr Vanessa Kay, Co-Director DIHS (R) and Dr ...

While there is no cure for Parkinson’s disease, there’s now a better way to control its involuntary muscle movements. In February, the FDA approved Medtronic’s BrainSense adaptive deep brain ...